Results for "Candel Therapeutics"

The biotechnology company sees its stock reach $13.96, reflecting renewed investor confidence in its clinical pipeline and therapeutic development progress.

Candel Therapeutics has announced the designation of Mark Sims as its new Chief Commercial Officer, a key leadership change for the company.

Candel Therapeutics has announced a proposed public offering aiming to raise $100 million.

A group of publicly traded companies across healthcare, consumer, and industrial sectors have announced plans to present at upcoming September investor conferences. The events will feature management teams discussing corporate strategy and financial outlooks with institutional investors.

Candel Therapeutics has announced its financial results for the first quarter, reporting a loss for the period.

Candel Therapeutics has priced a public offering aiming to raise $100 million.

Candel Therapeutics has entered into a $100 million funding agreement with RTW Investments and simultaneously launched a $100 million public offering.

Candel Therapeutics reported a GAAP EPS of -$0.52, missing estimates by $0.29, while Cellectar Biosciences reported a GAAP EPS of -$0.57, missing by $0.05.

Candel Therapeutics announced its GAAP EPS for the fourth quarter was -$0.54.

Candel Therapeutics has priced a $100 million public offering at $5.45 per share.